Espansione Group

Casa
Italia
Argelato
Espansione Group

We Science Onward. Redefining Paradigms in Ophthalmology and Beyond.

Since 1981, Espansione Group has delivered the highest standard in the Ophthalmology and Dermatology industries—pushed on by expert craftsmanship and family-owned values coupled with a global mindset and aspiration. Every day, we invest heavily in researching and developing the Espansione Ecosystem of technologies and solutions to achieve our ambition. Our ambition isn’t limited to that of becoming the undisputed thought leader in diagnosing and treating ocular surface conditions. Beyond that, we aim at leveraging our know-how and applying it synergically in other fields beyond ophthalmology. We have already delivered great degrees of innovation to the fields of ophthalmology and dermatology through our patented technology Light Modulation® Low-Level Light Therapy and its seamless integration in the Espansione Ecosystem of solutions. LM® LLLT has set a new medical standard in painlessly and effectively treating the majority of ocular surface conditions, on top of being extremely effective in its dermatology applications.

25/03/2026

Targeting early structural changes in AMD is becoming an increasingly relevant focus in retina care.

In the LightWave I randomized, sham-controlled trial, a patient with intermediate AMD (AREDS 3) completed two cycles of LM™ LLLT (PBM) with eye-light® over 12 months.

OCT-based follow-up demonstrated a reduction in mean drusen volume, consistent with the statistically significant MDV reduction observed across the PBM-treated cohort — suggesting a potential effect on key structural biomarkers of disease progression.
PBM, a non-invasive intervention, is hypothesized to act through mitochondrial modulation and reduction of oxidative stress.

As clinical evidence continues to expand, ongoing prospective studies will further clarify its role within the AMD therapeutic landscape.

Dive deeper in our scientific bibliography → https://www.espansionegroup.it/bibliography/ -segment

03/03/2026

Managing intermediate AMD requires strategies that support function before progression to advanced stages.

In the LightWave I study, a 73-year-old male patient with intermediate AMD (AREDS 3) underwent two treatment cycles of LM™ LLLT (PBM) delivered with eye-light® over a 12-month period.

At baseline, BCVA was 75 ETDRS letters (20/32). At 12-month follow-up, BCVA improved to 80 ETDRS letters (20/25), reflecting an objective functional enhancement within a structured treatment protocol.

This highlights the potential of PBM to support retinal function, providing measurable anatomical and functional benefits and illustrates the potential role of LM™ LLLT as a practical, non-invasive approach to support retinal function in everyday clinical practice.

👏 Special thanks to Prof. Murat Hasanreisoglu, MD – Koç University, Turkey, for his contribution to this case.

Dive deeper into the scientific evidence → https://espansionegroup.it/bibliography/ -segment

20/02/2026

Real-life impact of PBM in AMD, on AMD Awareness month

In clinical practice, an 85-year-old patient with intermediate dry AMD showed a significant anatomical improvement after just one cycle of PBM (8 sessions), including a marked reduction of a large pigment epithelial detachment (PED).
This case illustrates the potential of LM™ LLLT (PBM) as a practical, non-invasive tool to support retinal structure and function in everyday clinical practice.

👏 Thanks to Dr. Ximena Mira Lorenzo, MD – Centro Oftalmologico Arcos, Mexico City, Mexico.

👉Dive deeper into the scientific evidence: https://espansionegroup.it/bibliography/ -segment

05/02/2026

👁️ February is AMD Awareness Month

Age-Related Macular Degeneration (AMD) is a growing global health challenge, affecting millions of people worldwide—and the numbers continue to rise as populations age.

Early detection makes a difference.
When AMD is identified and treated in its early stages, disease progression can be slowed and vision can be preserved, protecting independence and quality of life.

Together with EssilorLuxottica and Heidelberg Engineering, Espansione Group is committed to advancing awareness, timely diagnosis and innovative solutions—key steps toward better outcomes for patients and healthcare systems alike.

This month, we join the global effort to raise awareness about AMD and the importance of acting early.

22/01/2026

Mucus Fishing Syndrome (MFS) is a chronic inflammatory condition of the ocular surface, characterized by repetitive mechanical removal of mucus that perpetuates inflammation and epithelial damage.

In a recent case series Mancini et al. (2025), prove the effectiveness of LM™ LLLT Photobiomodulation as an adjunctive therapy for the multimodal management of MFS.

In this study, two patients with persistent MFS, refractory to conventional therapy, showed significant improvements in tear film stability, mucus reduction and ocular discomfort after LM™ LLLT.

These preliminary results indicate that LM™ LLLT holds significant potential in the management of complex ocular surface conditions such as MFS, supporting its broader applicability across ocular surface care.

👉 Read the full paper : https://pubmed.ncbi.nlm.nih.gov/41487120/

12/12/2025

As the year comes to an end, we are excited to unveil the first new appointments for the 2026 In-Sight Webinar Series featuring fresh scientific insights across retinal and ocular surface disease.

Starting this month, the series will feature new sessions derived from our ESCRS and EURETINA 2025 scientific coverage, including:

•AMD & Photobiomodulation: The evolving role of mitochondrial health and PBM therapy
•Dry Eye in Surgical Candidates: Light Therapy for Tear Film Optimization in the Vision Correction Surgery Workflows
•Managing Ocular Surface Health in Glaucoma Patients: LM™ LLLT to Restore Tear Film, Relieve Symptoms and increase QOL
•TFOS DEWS III Deep Dive: What's New with the Global Consensus in the Ocular Surface Disease: Diagnosis to Treatment
•Long-Term Management of MGD Dry Eye: Evidence-based Triple-therapy for Chronic Care

Why attend?
These webinars deliver practical, clinically actionable insights to help you navigate the latest diagnostic and therapeutic pathways.

This is only the beginning—more expert-led episodes will follow soon.

Explore the new series and secure your seat for upcoming sessions.
👉 Register now: https://app.livestorm.co/espansione-group?lang=en

08/12/2025

Floretina 2025 has wrapped up, leaving us with fresh ideas, meaningful clinical insights and a renewed sense of purpose.

The discussions around light-based technologies — including LM™ LLLT (PBM) — and data-driven approaches were particularly inspiring and strengthened our commitment to supporting the scientific community with robust evidence and real-world clinical outcomes.

A heartfelt thank you to our outstanding team for their dedication and energy throughout the congress.

We are also deeply grateful to our KOLs — Claudio Iovino, Sibel Demirel, Pasquale Viggiano, Kelvin Teo, Enrico Borrelli and Rosa Dolz Marco — for their continued trust in LM™ LLLT (PBM) and for taking the time to engage with us and share their perspectives.
It is a privilege to collaborate with experts who are actively shaping the future of retinal care.

Our appreciation also extends to our colleagues at EssilorLuxottica, Heidelberg Engineering and RetinAI, whose collaboration and shared commitment to innovation remain invaluable

We leave Florence energized, aligned and more focused than ever on advancing evidence-based, light-driven technologies that address the clinical needs shaping the future of retinal care.

06/12/2025

How can non-invasive PBM support retinal microcirculation and visual function in intermediate AMD?

Tomorrow at FLORetina 2025, Dr. Mariapia Laterza will present new insights on how LM™ LLLT Photobiomodulation (PBM) may enhance retinal microcirculation and low-light vision in intermediate AMD.

📅 Sunday, December 7th — 10:09
📍 Del Carmine Room

Her session highlights PBM’s potential as a safe, non-invasive approach to support retinal health at a stage where therapeutic options are still limited.

Stop by Booth #56 to explore what’s next in non-invasive retinal care.

05/12/2025

How can non-invasive light-based therapy support early-stage AMD?

Discover the answer at FLORetina 2025 during Dr. Claudio Iovino's session on the LightWave I, a multicenter, randomized, double-masked clinical trial exploring LM™ LLLT Photobiomodulation (PBM) in early and intermediate dry AMD.

📅 Saturday, December 6th — 14:28
📍 San Giovanni Room

Dr. Claudio Iovino will discuss how PBM may offer a safe, non-invasive way to manage early structural and functional changes in dry AMD, at a stage where few therapeutic options exist.

Stop by Booth #56 to learn more about the future of non-invasive retinal care.

27/11/2025

We’re looking forward to seeing you all at FLORetina 2025.

After achieving great resonance in Anterior Segment care, we are bringing our core light-based technology LM™ LLLT Photobiomodulation (PBM) to the back of the eye.

If you share our ambition to slow down progression of the disease, stop by 📍 Booth #56 and join us on our mission to advance non-invasive management of Age-related Macular Degeneration.

📅 Curious to learn more?
👇 Don’t miss this year’s faculty sessions on our technology.

Dr. Claudio Iovino
"12-Months Outcomes of PBM in Intermediate AMD: A Prospective Multicenter Randomized Controlled Clinical Trial

🗓️ Saturday, December 6th
🕒 14:28
📍 San Giovanni Room

Dr. Mariapia Laterza
"Photobiomodulation-induced Choriocapillaris Perfusion Enhancement and Outer Retinal Remodelling in Intermediate Age-Related Macular Degeneration: a Promising Therapeutic Approach with Short-term Results"

🗓️ Sunday, December 7th
🕒 10:09
📍 Del Carmine Room

⚡️One more thing...

This year at FLORetina 2025 we’re joined by our colleagues from EssilorLuxottica, Heidelberg Engineering and Retinai .

👉 Come and join us in shaping what’s next in ophthalmology—we can’t wait to see you all in Florence.

06/11/2025

The ocular microbiome is central to ocular surface health, and Demodex infestation is a major driver of blepharitis and dry eye disease.

A new peer-reviewed study (Farrant S. et al., Clin Ophthalmol. 2025) demonstrates the effectiveness of eye-light® combining OPE™ IPL and LM™ LLLT (blue + red light) in managing treatment-resistant Demodex blepharitis.

Key outcomes:
✅ Significant reduction in collarettes & saponification
✅ Improved ocular surface parameters (CFS, hyperemia)
✅ Symptom relief (DEQ-5 ↓ from 12.0 → 7.8)
✅ No adverse events reported

By targeting both mite eradication and ocular surface health, our light-based protocol offers a comprehensive, safe, and patient-friendly solution for Demodex blepharitis.

At Espansione, we remain committed to advancing evidence-based innovation in ophthalmology.

23/10/2025

A breakthrough in ocular surface protection: results from a randomized, double-masked trial highlight the effectiveness of LM™ LLLT (PBM) in reducing Iatrogenic Dry Eye Disease after cataract surgery.

Conducted on a real-life surgical cohort, the therapy was safe, feasible to implement perioperatively, and readily adaptable to standard cataract surgery protocols.

The study found statistical significance in the following results:
✅ Improvements in OSDI and tear film break-up time
✅ Stabilization of tear osmolarity
✅ Preservation of corneal epithelial integrity

This reinforces the importance of device-based, non-invasive therapies in modern ophthalmology and sets a foundation for the integration of LM™ LLLT into routine surgical care.

Acknowledging the outstanding work of the authors: Mihaela-Madalina Timofte-Zorila, Daniel Constantin Branisteanu & team.

Indirizzo

Blocco 27 – Via Degli Orefici 152
Argelato
40050

Sito Web

http://espansionegroup.it/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Espansione Group pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Espansione Group:

Scelte rapide

Vuoi che la tua studio sia il Clinica più quotato a Argelato?

Digitare

Oculista

About Espansione Group

ESPANSIONE GROUP was founded in Italy in 1981. The company was born from the desire to provide our customers with certified medical technologies with the utmost seriousness and know-how. We produce in Italy and sell worldwide to the main hospitals and specialized medical facilities, extremely sophisticated diagnostic and surgical equipment. Our focus is on delivering high quality service and innovative technology to healthcare professionals worldwide, so they can provide better services to patients.